NAD+ Injections & 'NAD Peptide': Benefits, Dosage, Cost and the Evidence

Key takeaways

• NAD+ (nicotinamide adenine dinucleotide) is a coenzyme built from a vitamin B3 derivative, two sugars, two phosphates and adenine. It is not a peptide. Clinics sell it next to peptides because it is injected, compounded by the same pharmacies and marketed for the same reasons.
• The human evidence is mostly about blood levels. Oral precursors (nicotinamide riboside, NMN) reliably raise NAD+ in blood cells; a 2019 pilot found that infused NAD+ is cleared from plasma within two hours and broken down before cells can take it up; no trial has ever tested NAD+ injections or infusions against an outcome in healthy adults.
• The one large outcome trial of an NAD+ precursor, NOPARK (410 people with early Parkinson's disease, 1,000 mg of nicotinamide riboside a day for a year, JAMA, October 2026), found no benefit and slightly worse symptom scores than placebo.
• Studied doses are 250 to 2,000 mg a day of oral precursors and 500 to 1,000 mg per intravenous session in pilot studies. The subcutaneous schedules clinics use (roughly 50 to 500 mg a week) have no trial behind them at all. Fast infusions cause nausea, cramping, flushing, a racing heart and chest pressure.
• Legal status: no FDA-approved NAD+ drug exists. NAD+ sits in Category 1 of FDA's interim 503A list, so licensed pharmacies can compound it while FDA evaluates it, but FDA proposed in 2019 not to add it to the permitted list and has not finished that rulemaking. In 2024 FDA warned about injections made from food-grade NAD+; a Class I recall followed in 2025.

NAD+ (nicotinamide adenine dinucleotide) at a glance

Also called

NAD, beta-NAD, NAD injection, NAD+ IV, NAD peptide (a misnomer)

Class

Coenzyme (a pyridine dinucleotide). It is not a peptide; it contains no amino acids

Route

Intravenous infusion at clinics; subcutaneous or intramuscular injection at home; nasal spray. Oral precursors (nicotinamide riboside, NMN) are sold as supplements

FDA status

No FDA-approved NAD+ drug exists. NAD+ was nominated for FDA's 503A bulks list and sits in Category 1 of the interim list (compounding tolerated while under evaluation), but FDA proposed in September 2019 not to add it and has not finalized that rule. In 2024 FDA warned that some compounders were making injections from food-grade NAD+.

FDA Category 2 (compounding restricted)

No

Available by prescription (US)

Yes, compounded on prescription under FDA's interim Category 1 policy

Best-studied use

Pharmacokinetics of a 6-hour infusion in a handful of adults; oral precursors (NR, NMN) in small trials of blood NAD+ and metabolic surrogates; one negative phase 3 outcome trial of NR in Parkinson's disease. No outcome trial of NAD+ injections or infusions in healthy adults.

Typical monthly cost (telehealth, 2026)

$105 to $350 a month for at-home injections; $116 to $200 a month for nasal spray; $250 to $1,500 per clinic IV session (October 2026)

What NAD+ is, and why it is not a peptide

Nicotinamide adenine dinucleotide is a small molecule present in every living cell. Chemically it is two nucleotides joined through their phosphate groups: one carries nicotinamide, a form of vitamin B3, and the other carries adenine. There is no chain of amino acids anywhere in it, so it is not a peptide, however many clinic menus file it under "NAD peptide" or "peptide NAD+". A peptide is a short protein fragment; NAD+ is closer to a vitamin that has been assembled into a working part.

What it does is central to metabolism. NAD+ accepts electrons from the breakdown of food and hands them to the mitochondria, cycling between its oxidized form (NAD+) and its reduced form (NADH) thousands of times a day. It is also consumed, rather than recycled, by the enzyme families that made it a longevity target: sirtuins, which regulate gene expression and stress responses; PARPs, which repair DNA; and CD38, an immune enzyme. Cells rebuild it continuously from precursors: nicotinamide, nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), niacin and tryptophan.

The case for topping it up rests on two observations. In rodents, tissue NAD+ falls with age and restoring it improves a range of age-related measures. In humans the evidence is thinner: in skin samples from 49 people aged from birth to 77, tissue NAD+ fell with age in both sexes while PARP activity rose, consistent with DNA damage consuming the pool (Massudi 2012). But recent large human datasets show that whole-blood NAD+ does not decline with healthy aging as such, and that low NAD+ tracks metabolic dysfunction more than birthdays (Alangari 2026). "Replace what aging took from you" is a tidier story than the data support.

Why NAD+ is sold with peptides

Three practical reasons, none of them chemical. NAD+ is injected or infused, so it fits the same workflow as sermorelin or a GLP-1 drug; it is compounded by the same 503A pharmacies and prescribed through the same telehealth consultations; and it is marketed for the same promises: energy, recovery, longevity. "NAD peptide" is now one of the most-searched phrases in this field, and most people typing it are asking a sensible question with a one-word answer: no.

What the evidence actually shows

Three different things get lumped together as "NAD therapy", and they do not share an evidence base. Oral precursors (NR and NMN supplements) account for almost all the controlled trials. Intravenous NAD+ has a handful of pilot studies, none placebo-controlled with a clinical outcome. Subcutaneous and intramuscular NAD+ injections, the product most telehealth programs sell, have no published human trials at all. Here is the honest grading.

NAD+ claims, graded by the evidence behind them

Claim	Grade	What the evidence shows	Sources
Raises NAD+ in the blood (oral precursors)	B	In 24 adults aged 55 to 79, nicotinamide riboside 500 mg twice daily for 6 weeks raised NAD+ in blood cells by about 60% versus placebo in a crossover trial. Multiple small trials of NMN at 250 to 900 mg a day show the same. The rise is reliable; what it does is the open question.	Martens 2018; Yang 2026
Infused NAD+ enters your cells intact	D	In the only published pharmacokinetic study, 750 mg of NAD+ infused over 6 hours produced no rise in plasma NAD+ or its metabolites for the first 2 hours; the molecule was removed from plasma almost completely, and the metabolite pattern fit breakdown by extracellular enzymes rather than uptake. NAD+ itself and methylnicotinamide appeared in urine by hour 6.	Grant 2019
Improves insulin sensitivity or metabolic health	C	Mixed. In 25 postmenopausal women with prediabetes who were overweight or obese, NMN 250 mg a day for 10 weeks increased muscle insulin sensitivity on a clamp study while placebo did not. In 40 obese, insulin-resistant men, NR 2,000 mg a day for 12 weeks changed nothing: not insulin sensitivity, glucose production, energy expenditure or body composition. A 2026 meta-analysis of 15 NMN trials found no effect on weight, BMI, fasting glucose, HbA1c or lipids.	Yoshino 2021; Dollerup 2018; Yang 2026
Improves muscle, strength or physical function in older adults	C	A 2025 meta-analysis of randomized trials in adults with a mean age over 60 found no effect of NMN or NR on muscle mass index, grip strength, gait speed or chair-stand time, and no improvement in knee extension strength or thigh muscle mass.	Prokopidis 2025
Lowers blood pressure or arterial stiffness	C	In the 6-week crossover trial, systolic pressure was 3.9 mmHg lower on NR than placebo, which was not significant after correction; a post-hoc look at the 13 participants with elevated baseline pressure showed a 9 mmHg difference that the authors said could not support inference. The 2026 NMN meta-analysis found a small fall in diastolic pressure and none in systolic.	Martens 2018; Yang 2026
Slows neurodegeneration (Parkinson's disease)	B	Negative. In NOPARK, 410 people with early Parkinson's disease took NR 500 mg twice daily or placebo for 52 weeks. Total MDS-UPDRS scores worsened by 2.45 points on NR and improved by 0.27 on placebo, an adjusted difference of 2.72 points favoring placebo; non-motor symptom burden also worsened more on NR. Serious adverse events were not higher on NR (8.3% versus 14.1%).	Brakedal 2026
Slows aging or extends healthspan	D	No trial has measured an aging outcome. Tissue NAD+ falls with age in human skin, but whole-blood NAD+ does not decline with healthy aging in large datasets, and the 2026 review of intravenous NAD+ concluded the evidence is insufficient to support routine clinical or wellness use.	Massudi 2012; Alangari 2026
IV NAD+ is well tolerated	C	At a slow rate (750 mg over 6 hours) no adverse events were reported. In a retrospective review of a commercial clinic, all 6 clients given 500 mg daily for four days reported moderate to severe abdominal cramping, nausea, vomiting, a faster heart rate and chest pressure during the drip; infusions averaged 97 minutes because clients slowed them, and all symptoms resolved when the infusion ended. Long-term safety data do not exist.	Grant 2019; Reyna 2026; Alangari 2026

Four things stand out from that table.

First, the precursor trials measure a biomarker, not a benefit. Raising NAD+ in blood cells by 60% is a real pharmacological effect, and the one the industry cites. The trials that then looked for a clinical consequence, in insulin-resistant men, in older adults' muscles, in a 15-trial meta-analysis, mostly found nothing. The one clear positive, better muscle insulin sensitivity in 25 prediabetic women (Yoshino 2021), has not been replicated at scale and did not translate into weight or glucose changes in the pooled data (Yang 2026).

Second, the one outcome trial was negative. NOPARK is the best-designed test of the "more NAD+ is better" idea ever run: 11 centers, 410 patients, a year of treatment, a validated endpoint. The result was worse motor and non-motor scores on NR (Brakedal 2026). Parkinson's disease is not healthy aging and NR is not an NAD+ drip, but it is the closest thing to a verdict on the hypothesis that exists, and it should make anyone cautious about claims that pushing NAD+ up is harmless by definition.

Third, infused NAD+ does not behave the way the brochure says. The pilot study that gave 750 mg over six hours was designed to see where the molecule goes. Plasma NAD+ did not rise for two hours because the infused NAD+ was stripped out as fast as it arrived, with a metabolite profile matching the enzymes that cut NAD+ apart outside cells (Grant 2019). NAD+ is a large, charged molecule that cells do not import intact; what they take up are the fragments, mainly nicotinamide, which a vitamin tablet also supplies. That is not proof that infusions do nothing. It is proof that "delivering NAD+ directly to your cells" is a marketing sentence, not a pharmacokinetic one.

Fourth, injections have no data. The 2026 narrative review found human evidence for intravenous NAD+ limited to small uncontrolled studies and case reports, with no controlled outcome trial (Alangari 2026). For subcutaneous and intramuscular injections, the product most people actually buy, we could not find a single published human study, and a February 2026 systematic review cited by Science-Based Medicine found no eligible controlled outcome trials of NAD+ by any injected route (Gavura 2026).

What you are promised versus what is documented

NAD+ marketing lists more energy, sharper thinking, better sleep, faster recovery, "cellular repair", addiction recovery, weight loss and anti-aging. The evidence sorts those into three bins.

• Documented in humans: oral NR and NMN raise NAD+ and related metabolites in blood; a transient rise in circulating NAD+ metabolites during and after an infusion; short-term tolerability of oral precursors at up to 2,000 mg a day.
• Plausible but unproven: better muscle insulin sensitivity in prediabetic women; a small blood-pressure effect; subjective energy and sleep reports from uncontrolled infusion series.
• Not supported: anti-aging or healthspan extension, weight loss, cognitive enhancement, addiction or withdrawal treatment, athletic performance, hangover recovery, and any benefit specific to injecting NAD+ rather than swallowing a precursor.

The bin that matters for your wallet is the second one. Nothing in it required a drip; everything in it was produced by a capsule.

NAD+ injections vs IV vs oral precursors vs nasal spray

Prices are from our peptide therapy cost guide, collected October 9, 2026. The honest comparison is uncomfortable for the injectable market: the route with the most evidence is the cheapest one, and the routes that cost the most have the least.

Dosage: what was studied versus what clinics use

Two points about the arithmetic. The oral precursor doses are measured in grams a day for weeks; a 100 mg subcutaneous shot once a week is a fraction of that exposure by a route nobody has studied. And the intravenous dose that produced symptoms (500 mg over about 97 minutes) and the one that produced none (750 mg over 360 minutes) differ mainly in speed, which is why experienced clinics run drips over two to four hours, a preference the 2026 review calls anecdotal rather than tested (Alangari 2026).

Infusion speed

The symptoms of a fast NAD+ drip are consistent enough to recognize: nausea, abdominal cramping, flushing, a faster pulse and pressure in the chest. In the retrospective clinic series every NAD+ client had them, every one resolved when the infusion ended, and the clients slowed their own drips, which is why NAD+ infusions took almost three times as long as nicotinamide riboside infusions in the same clinic (Reyna 2026). Chest pain that does not ease when the drip is slowed, shortness of breath, fainting or a rash are not rate effects and need medical evaluation.

Dose arithmetic for an at-home vial

Compounded NAD+ injection is usually dispensed as a ready-made solution rather than a powder, and the concentration varies by pharmacy. If your vial is labeled 200 mg/mL, a 100 mg dose is 0.5 mL, which reads as 50 units on a standard U-100 insulin syringe; from a 100 mg/mL vial the same dose is 1 mL, or 100 units. If your pharmacy ships lyophilized powder instead, run the numbers in the reconstitution calculator and trust the label over the calculator if they disagree. Technique is the same as for any compounded injectable; see how to inject peptides.

Side effects and who should not use it

Oral precursors. In the 6-week NR trial the adverse events on NR were nausea, flushing, leg cramps and easier bruising, one case each, all mild, with more events during the placebo phase (Martens 2018). The 2026 meta-analysis found no increase in adverse events across 15 NMN trials at 250 to 2,000 mg a day and no rise in liver enzymes (Yang 2026); 12 weeks of 2,000 mg a day of NR produced normal safety bloods in 40 obese men (Dollerup 2018).

Infusions. The infusion reactions above, which track dose and speed. The 2026 review lists nausea, cramping, flushing and chest discomfort as the reported adverse effects and notes that long-term safety data are lacking, especially in people with kidney disease, liver disease or cancer (Alangari 2026).

Product quality. This is the risk that has actually hurt people. In 2024 FDA said it was aware of compounders using food-grade NAD+ from repackagers to make intravenous products, that such material carries a high risk of microbial and endotoxin contamination, and that it had received reports after NAD+ injections of severe chills, shaking, vomiting and fatigue, some requiring medical treatment, consistent with excessive endotoxin (FDA 2024). In 2025 FDA issued a Class I recall, its most serious category, of an NAD+ injection made by GenoGenix LLC for elevated endotoxin (Gavura 2026). An endotoxin reaction looks like a severe flu starting within an hour or two of the injection; it is a medical problem, not a "detox" effect.

Unknowns. Nobody has followed infusion patients for years. Proliferating cells, including cancer cells, use NAD+ heavily, and the 2026 review flags effects on malignancy as a theoretical concern that preclinical work has neither confirmed nor excluded. NOPARK is a reminder that a year of high-dose precursor was associated with worse outcomes in one disease.

Do not use NAD+ injections or infusions, or use them only with a specialist's sign-off, if you have:

• an active cancer or a recent cancer history;
• Parkinson's disease or another neurodegenerative diagnosis, until the NOPARK signal is understood;
• unstable heart disease, arrhythmia or uncontrolled hypertension, because infusions raise heart rate and cause chest pressure;
• pregnancy or breastfeeding, where there are no data;
• a plan to use it in place of supervised addiction or withdrawal treatment.

Legal status in the United States

NAD+ is in a stranger position than most compounded products, and the short version in our legal tracker deserves the long version.

• There is no approved NAD+ drug. No company has taken NAD+ through FDA review for any indication, so it reaches patients only as a compounded preparation.
• It is in Category 1 of FDA's interim 503A list. When a substance is nominated for the list of bulk ingredients that 503A pharmacies may compound, FDA sorts it into interim categories while it evaluates. On the September 29, 2023 revision of that list, "Nicotinamide Adenine Dinucleotide (NAD)" and NADH appear in Category 1: nominated with enough information to evaluate, and not subject to enforcement action while the evaluation is pending (FDA interim categories 2023); FDA's May 14, 2026 update still lists both there (FDA categories 2026). That is the legal basis a pharmacy will cite. A separate entry, beta-NAD disodium salt trihydrate, sits in Category 3 (nominated without adequate support), which carries no such protection, so the form a pharmacy buys matters.
• But FDA has already said it does not want NAD+ on the final list. On September 5, 2019, after consulting its advisory committee and USP, FDA published a proposed rule that would add five substances to the 503A bulks list and decline 26 others, including nicotinamide adenine dinucleotide and NADH (Federal Register 2019). As of October 9, 2026 we found no final rule. Until FDA finalizes it, NAD+ stays in Category 1 and compounding continues; if FDA finalizes it as proposed, NAD+ compounding under 503A ends. A clinic that tells you NAD+ is "FDA-approved for compounding" has the direction of travel backwards.
• Outsourcing facilities are a separate question. 503B facilities work from a different list, the 503B clinical-need list, and a facility selling NAD+ should be able to tell you the basis on which it does.
• Quality enforcement has started. The 2024 reminder about food-grade NAD+ and the 2025 recall are the first FDA actions aimed at this market. Ask whether the pharmacy uses pharmaceutical-grade NAD+ and documents endotoxin testing.
• The precursors have their own story. Nicotinamide riboside is sold as a dietary supplement. FDA declared NMN excluded from the supplement definition in November 2022 because it had been authorized for drug investigation; after a 2023 citizen petition and a 2024 lawsuit by the Natural Products Association, FDA reversed itself in a letter dated September 29, 2025, concluding that NMN had been marketed as a supplement in the US before the drug authorization and is not excluded, though new-dietary-ingredient notifications are still required (NutraIngredients 2025). Nothing in that decision concerns injectable NAD+.

Cost and how to get it prescribed

As of October 2026, US telehealth programs list compounded NAD+ for at-home injection at roughly $105 to $350 a month, nasal spray at $116 to $200 a month, and clinic IV sessions at $250 to $1,500 each; see the cost guide for the sources. Insurance covers none of it. Oral NR and NMN cost a fraction of the injectable price.

If, having read the evidence, you still want NAD+ prescribed, the legitimate path looks the same as for any compounded injectable: a clinician licensed in your state who reviews your history (cancer, heart disease, pregnancy, neurological diagnoses); a named 503A pharmacy or 503B facility that can state its legal basis (the Category 1 interim policy) and its ingredient grade; a vial labeled with the concentration and a beyond-use date, with endotoxin and sterility testing on file; and nobody promising outcomes.

Red flags are the mirror image: drips sold by the bag at a med spa with no prescriber, "NAD peptide" bundled into a longevity stack with peptides that no pharmacy may compound, research-grade powder with mixing instructions, or any claim that an NAD+ product is FDA-approved.

NAD+ for women and older adults

The best metabolic result for an NAD+ precursor came in women: the 10-week NMN trial that improved muscle insulin sensitivity enrolled only postmenopausal women with prediabetes who were overweight or obese (Yoshino 2021). It is a single small trial, and the pooled data in both sexes show no effect on glucose or weight, but it is the one place where "NAD+ for metabolic health" has a human signal. There are no data in pregnancy or breastfeeding, and no reason to use it then.

For older adults the picture is the opposite of the marketing. The crossover trial that established NR's safety enrolled people aged 55 to 79 and found the NAD+ rise, but no functional change (Martens 2018), and the 2025 meta-analysis of trials in adults over 60 found no benefit for muscle mass, grip strength or gait speed (Prokopidis 2025). Older adults have the most to gain if NAD+ repletion worked, and are the group in which it has most clearly not been shown to.

Bottom line

NAD+ is a coenzyme, not a peptide, and the fact that it is sold with peptides tells you about the business, not the biology. The oral precursors raise NAD+ in blood reliably and safely for a few months, and the trials that then looked for a clinical benefit mostly did not find one; the one large outcome trial, in Parkinson's disease, was negative. Infused NAD+ is broken down before cells can take it in, and no study has tested NAD+ injections against anything. What the market has is a legal basis FDA has signaled it wants to withdraw, and a contamination problem FDA has already acted on.

A reasonable use is an oral precursor, if you want to run the experiment on yourself cheaply. An unreasonable use is a subscription to injections, or a $500 drip, bought on the promise of longevity.

Frequently asked questions

+−Is NAD a peptide?

No. NAD+ (nicotinamide adenine dinucleotide) is a coenzyme built from two nucleotides: one carries nicotinamide, a form of vitamin B3, and the other carries adenine. It contains no amino acids and no peptide bond. It is sold next to peptides because it is injected, compounded by the same pharmacies, prescribed by the same telehealth clinics and marketed for the same reasons, which is why 'NAD peptide' has become a common search term. The chemistry is different, and so is the evidence.

+−What does the NAD injection do?

Measurably, an injection or infusion raises NAD+ and its breakdown products in the blood for a few hours. The 2019 pilot study of a six-hour infusion found that infused NAD+ was removed from plasma almost completely for the first two hours and that the metabolites fit extracellular breakdown rather than uptake into cells. What that does for energy, aging, mood or recovery has never been tested in a controlled trial. The benefits people report after a drip are real experiences, but they are uncontrolled and unblinded.

+−What is the downside of taking NAD?

For infusions, the common problems are nausea, abdominal cramping, flushing, a racing heart and chest pressure during the drip, which fade when the infusion slows or stops. For injections and drips in general, the larger risk is product quality: in 2024 FDA warned that some compounders were making injectable NAD+ from food-grade powder, with adverse-event reports of severe chills, shaking and vomiting consistent with endotoxin contamination, and a Class I recall of one NAD+ injection followed in 2025. Long-term safety has not been studied, and the only large outcome trial of an NAD+ precursor, in Parkinson's disease, found slightly worse symptom scores than placebo.

+−Is NAD like Ozempic?

No. Ozempic (semaglutide) is a GLP-1 receptor agonist that lowers appetite and blood sugar and has large outcome trials behind it. NAD+ is a coenzyme involved in energy metabolism with no weight-loss trial in humans; a 2026 meta-analysis of 15 trials of oral NMN found no effect on body weight, BMI, glucose or HbA1c. Some clinics bundle NAD+ with a GLP-1 drug; there is no trial of that combination.

+−Is NAD+ like Adderall?

No. Adderall is an amphetamine stimulant that acts on dopamine and norepinephrine signaling. NAD+ is not a stimulant and does not act on those systems. People sometimes describe more energy after an infusion, but that is a subjective report from uncontrolled settings, and the one placebo-controlled trial that measured physical function and fatigue-related scores over a year, in Parkinson's disease, found no benefit.

+−Is NAD safe?

Short-term oral precursors look safe in trials: nicotinamide riboside at 1,000 to 2,000 mg a day for 6 to 12 weeks and NMN at 250 to 900 mg a day produced no more adverse events than placebo. Intravenous NAD+ causes infusion reactions that resolve when it stops, and its long-term safety is unknown because nobody has followed infusion patients for years. Two cautions stand out: contamination of poorly made injectable products (FDA's 2024 alert and a 2025 recall) and the NOPARK trial, in which a year of high-dose nicotinamide riboside was associated with worse Parkinson's scores than placebo. People with an active cancer, who are pregnant or breastfeeding, or who have unstable heart disease should not use it without a specialist's agreement.

+−How much are NAD injections?

In October 2026, telehealth programs list at-home NAD+ injections at about $105 to $350 a month, nasal spray at $116 to $200 a month, and clinic IV sessions at $250 to $1,500 each depending on the dose and the city. Insurance does not cover any of it. See our peptide therapy cost guide for the sources behind those figures.

+−Which is better, NAD or copper peptides?

They are different products for different claims. GHK-Cu is a genuine peptide used topically for skin texture and wrinkles, with small cosmetic studies behind it; injectable GHK-Cu cannot be legally compounded in 2026. NAD+ is a coenzyme given by injection or infusion for energy and anti-aging claims that no trial supports. Neither has human longevity data. If the goal is skin, topical GHK-Cu is the one with a legal product and some evidence; if the goal is living longer, neither has earned a recommendation.

+−Should you take NAD at night or in the morning?

No trial has compared times of day. The nicotinamide riboside and NMN trials simply dosed once or twice daily. Clinic advice to inject or infuse in the morning reflects reports of feeling wired or nauseated, not data. If a product keeps you awake, moving it earlier is reasonable; it is not evidence that timing changes what the molecule does.

+−Is there an NAD peptide dosing chart?

There is no dosing chart from a human study of NAD+ injections, because no such study exists. The published doses are 750 mg over six hours (one pharmacokinetic pilot), 500 mg daily for four days by IV (a retrospective clinic review) and 250 to 2,000 mg a day of oral precursors. The subcutaneous schedules clinics circulate, typically 50 to 100 mg one to three times a week up to several hundred milligrams weekly, were never tested against anything.

Sources

1. StudyGrant R et al. A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6 hour intravenous infusion of NAD+. Front Aging Neurosci 2019;11:257. (2019)
2. StudyReyna K et al. Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. Front Aging 2026;7:1652582. (2026)
3. ReviewAlangari A et al. Narrative review of intravenous NAD+ and NAD+ precursors in wellness and translational medicine. Front Aging 2026;7:1887175. (2026)
4. StudyMartens CR et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun 2018;9:1286. (2018)
5. StudyDollerup OL et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am J Clin Nutr 2018;108:343-53. (2018)
6. StudyYoshino M et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science 2021;372:1224-9. (2021)
7. ReviewYang W et al. Safety and metabolism-related outcomes of oral nicotinamide mononucleotide supplementation in adults: a systematic review and meta-analysis. Nutrients 2026;18:2251. (2026)
8. ReviewProkopidis K et al. The effect of nicotinamide mononucleotide and riboside on skeletal muscle mass and function: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle 2025;16:e13799. (2025)
9. StudyBrakedal B et al. Nicotinamide riboside for patients with early-stage Parkinson disease: the NOPARK randomized clinical trial. JAMA 2026 (published online October 8, 2026). (2026)
10. StudyMassudi H et al. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One 2012;7:e42357. (2012)
11. RegulatoryFDA. Bulk drug substances nominated for use in compounding under section 503A of the FD&C Act: interim Categories 1, 2 and 3 (revision of September 29, 2023, as reproduced by the Alliance for Pharmacy Compounding; NAD and NADH listed in Category 1). (2023)
12. RegulatoryFDA. Amendments to the list of bulk drug substances that can be used to compound drug products in accordance with section 503A; proposed rule (proposing not to include nicotinamide adenine dinucleotide and NADH). Federal Register, September 5, 2019. (2019)
13. RegulatoryFDA. FDA reminds compounders to use ingredients suitable for sterile compounding (food-grade NAD+ used in injectable products; adverse event reports consistent with endotoxins). 2024. (2024)
14. SourceGavura S. Science vs. hype: the unproven promise of NAD+ IV therapy. Science-Based Medicine, July 16, 2026. (2026)
15. NewsDaniells S. FDA declares NMN lawful in dietary supplements (FDA letter of September 29, 2025 reversing its November 2022 position). NutraIngredients-USA, September 30, 2025. (2025)
16. RegulatoryFDA. Bulk drug substances nominated for use in compounding under section 503A: Category 1, 2 and 3 lists and updates (updated May 14, 2026). (2026)